Cellular Biomedicine Closes Twelve-Month Follow-Up Of Patients On ReJoin Therapy

(RTTNews) - Cellular Biomedicine Group Inc.(CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced Wednesday that it completed of the twelve-month follow-up of patients from the Phase I/IIa trial, which evaluates the safety and efficacy of the Company's proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoin for Knee Osteoarthritis or KOA.

With treatment completed in 2013, all patients in the Phase I/IIa trial have now undergone twelve-month follow-up tests, which include WOMAC, NRS-11, SF-36 and KSCRS indices as well as knee articular cartilage volume assessment through quantitative magnetic resonance imaging or MRI evaluation.

The six-month follow-up data analysis previously concluded that ReJoin cell therapy for KOA patients is safe and revealed an increase in cartilage volume as early as three months after the therapy.

Dr. William Cao, Chief Executive Officer of the Company, said, "We are very pleased with the smooth progress of our trials for KOA. The excellent readout from the six-month follow-up of the Phase I/IIa trial makes us optimistic about the data from this twelve-month follow-up. We expect the official report to be available in the fourth quarter of 2014."

Cellular Biomedicine Group is currently running a multi-center Phase IIb clinical trial for ReJoin, which further studies the efficacy of CBMG's proprietary haMPC-based therapy for KOA.